The Pharmalot View By Ed Silverman Azar has a ‘tin ear’ when it comes to pricing a potential coronavirus treatment
The Pharmalot View By Ed Silverman Kapoor certainly deserves to go to jail, but so do some other pharma execs
The Pharmalot View By Ed Silverman The military pushed it for the battlefield. The FDA went along. Is the newest opioid any better?
The Pharmalot View By Ed Silverman From zero to hero: J&J CEO praises Trump one year after chastising him
The Pharmalot View By Ed Silverman Trump proposes importing medicines, but he’s really seeking a quick political hit
The Pharmalot View By Ed Silverman If the states don’t treat pharma as a utility, it may be ‘lights out’ for too many patients
The Pharmalot View By Ed Silverman Sanofi scandal in the Philippines could spread dangerous mistrust of vaccines
The Pharmalot View By Ed Silverman FDA commissioner needs to push back and tell Trump the agency is not part of the ‘deep state’
The Pharmalot View By Ed Silverman Where’s the data? In a pandemic, now is no time to sit on Covid-19 trial results
The Pharmalot View By Ed Silverman We shouldn’t rush to use an unproven malaria drug to treat the coronavirus
The Pharmalot View By Ed Silverman The FDA commissioner sweepstakes: Is Azar yearning to get out of Gottlieb’s shadow?
The Pharmalot View By Ed Silverman Grandstanding, not real change: Why drug prices in TV ads will be confusing and irrelevant
The Pharmalot View By Ed Silverman Forget about an international pricing index for drugs. Cost-effectiveness is a better bargain
The Pharmalot View By Ed Silverman Tweet this: Gottlieb’s leaving, and so is FDA’s highly effective communicator
The Pharmalot View By Ed Silverman Prepare for grilling: 7 questions for 7 pharma execs who’ll testify before Congress about prices
The Pharmalot View By Ed Silverman The list price is not right: Trump’s plan to force pharma to advertise prices is misguided
The Pharmalot View By Ed Silverman One of the world’s largest drug makers is paying docs again — and patients are the worse off
The Pharmalot View By Ed Silverman When modest is actually excessive: AstraZeneca spins its price hikes
The Pharmalot View By Ed Silverman He can shame Pfizer and others, but Trump doesn’t have a practical way to lower drug prices
The Pharmalot View By Ed Silverman Novartis’ tone-deaf response to Michael Cohen: troubling, but not surprising
The Pharmalot View By Ed Silverman The Pentagon wants to approve drugs for the battlefield. Here’s why that’s dangerous
The Pharmalot View By Ed Silverman California just passed a law to rein in drug prices. Here’s why it’s unlikely to make much difference
The Pharmalot View By Ed Silverman Here’s how a loophole in a transparency law can distort medical practices
The Pharmalot View By Ed Silverman This pharma CEO won praise for his ‘social contract’ with the public. But his latest move could shred that pledge
The Pharmalot View By Ed Silverman At $475,000, new cancer drug raises thorny questions about drug pricing — and value
The Pharmalot View By Ed Silverman Drug makers deserve to be publicly shamed for thwarting competition from generics
The Pharmalot View By Ed Silverman The art of the deal? Why a money-back guarantee for drugs is a bad idea
The Pharmalot View By Ed Silverman If drug companies are really ‘getting away with murder,’ Trump may be about to grant them a pardon
The Pharmalot View By Ed Silverman It’s time to make it legal for Americans to order prescription drugs from abroad
The Pharmalot View By Ed Silverman US taxpayers are funding a Zika vaccine. Let’s make sure US patients can afford it
The Pharmalot View By Ed Silverman The Trump administration could bring down drug prices. But it would take guts